Recruiting studies: Advanced Malignant Tumors Stage Ia Ib
Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →
A Study of AK129 in Patients With Advanced Malignant TumorsPhase 1 · 1 location(s) · Akeso · NCT05645276A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
Phase 1 · 8 location(s) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · NCT06615193A Study of CSCJC3456 in Patients With Advanced Malignant Tumors
Phase 1 · 2 location(s) · Changshan ConjuChem BioPharmaceutical Research and Developme · NCT06717750A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
Phase 1 · 3 location(s) · Proviva Therapeutics, Inc. · NCT06190886Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Phase 1 · 1 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT06418061MAQ-001 in Patients With Advanced Solid Tumors
Phase 1 · 4 location(s) · MabQuest SA · NCT06514651Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid T
Phase 1 · 1 location(s) · Chong Kun Dang Pharmaceutical · NCT07215637A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With C
Phase 1 · 41 location(s) · Genentech, Inc. · NCT05581004A Study of AK131 in Patients With Advanced Solid Tumors
Phase 1 · 1 location(s) · Akeso · NCT06166888A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Phase 1 · 3 location(s) · RasCal Therapeutics, Inc. · NCT04678648A Study of TPD3310 in Patients With Advanced Malignant Tumors
Phase 1 · 1 location(s) · TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD. · NCT07368127A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
Phase 1 · 14 location(s) · Chugai Pharmaceutical · NCT05907980A Study of TYK-00540 in Adult Patients With Solid Tumors
Phase 1 · 1 location(s) · TYK Medicines, Inc · NCT06246071SG1906 for CLDN18.2-Positive Solid Tumors
Phase 1 · 9 location(s) · Hangzhou Sumgen Biotech Co., Ltd. · NCT05857332A Phase Ia/ Ib Study of HS387 in Subjects With Advanced Solid Tumors
Phase 1 · 1 location(s) · Zhejiang Hisun Pharmaceutical Co. Ltd. · NCT07092748Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
Phase 1 · 1 location(s) · Massachusetts General Hospital · NCT06302621Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metast
Phase 1 · 1 location(s) · Lei Zheng · NCT07086768Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer
Phase 1 · 1 location(s) · Deborah Doroshow · NCT04997993A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combina
Phase 1 · 1 location(s) · Akeso · NCT05868876A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic
Phase 1 · 1 location(s) · Biocity Biopharmaceutics Co., Ltd. · NCT06548672A Phase Ia/Ib Clinical Study of GH56 Capsules in Subjects With MTAP-Deleted Advanced Solid Tumors
Phase 1 · 4 location(s) · Suzhou Genhouse Bio Co., Ltd. · NCT06796699A Study of HDM2012 in Patients With Advanced Solid Tumor
Phase 1 · 1 location(s) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · NCT07100249A Study of CBP-1008 in Patients With Advanced Solid Tumor
Phase 1 · 3 location(s) · Coherent Biopharma (Suzhou) Co., Ltd. · NCT04740398A Study of HDM2005 in Patients With Advanced Solid Tumor
Phase 1 · 1 location(s) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · NCT07004296A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors
Phase 1 · 1 location(s) · Suzhou Genhouse Bio Co., Ltd. · NCT06329206
Look up another condition
Patient organization or foundation? You can brand
this page for your community — your logo, your resources, same honest
registry data, kept current daily.
Ask about branding →
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.